OTCMKTS:CTTCCalmare Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Calmare Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.06 0.00 (0.00 %) (As of 08/4/2020 02:56 PM ET) Add Compare Share Today's Range$0.06Now: $0.06▼$0.0650-Day Range$0.06MA: $0.09▼$0.1252-Week Range$0.06Now: $0.06▼$0.20VolumeN/AAverage Volume3,200 shsMarket Capitalization$1.91 millionP/E RatioN/ADividend YieldN/ABeta0.65 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Calmare Therapeutics. Previous Next 1.9 Community Rank Outperform VotesCalmare Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCalmare Therapeutics has received 80 “underperform” votes. (Add your “underperform” vote.)Community SentimentCalmare Therapeutics has received 61.54% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Calmare Therapeutics and other stocks. Vote “Outperform” if you believe CTTC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTTC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCalmare Therapeutics does not currently pay a dividend.Dividend GrowthCalmare Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calmare Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 17.50% of the stock of Calmare Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.53% of the stock of Calmare Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.38 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CTTC Previous Symbol CUSIPN/A CIK102198 Webwww.calmaretherapeutics.com Phone203-368-6044Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees7 Outstanding Shares30,380,000Market Cap$1.91 million Next Earnings DateN/A OptionableNot Optionable $0.06 0.00 (0.00 %) (As of 08/4/2020 02:56 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CTTC News and Ratings via Email Sign-up to receive the latest news and ratings for CTTC and its competitors with MarketBeat's FREE daily newsletter. Calmare Therapeutics (OTCMKTS:CTTC) Frequently Asked Questions How has Calmare Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Calmare Therapeutics' stock was trading at $0.0995 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTTC stock has decreased by 36.7% and is now trading at $0.0630. View which stocks have been most impacted by Coronavirus. Has Calmare Therapeutics been receiving favorable news coverage? Media headlines about CTTC stock have trended very negative recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Calmare Therapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near future. View the latest news about Calmare Therapeutics. Who are some of Calmare Therapeutics' key competitors? Some companies that are related to Calmare Therapeutics include Invivo Therapeutics (NVIV), CELLECT BIOTECH/S (APOP), Encision (ECIA), Obalon Therapeutics (OBLN), Neurometrix (NURO), RA Medical Systems (RMED), Cytocore (MDIT), Regenicin (RGIN), Akorn (ELGXQ), Endologix (ELGX), TearLab (TEAR), AdvanSource Biomaterials Corpration (ASNB), Nuvectra (NVTRQ), Valeritas (VLRXQ) and Lombard Medical (EVARF). View all competitors. What other stocks do shareholders of Calmare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calmare Therapeutics investors own include Idera Pharmaceuticals (IDRA), Brainstorm Cell Therapeutics (BCLI), Costco Wholesale (COST), Blue Apron (APRN), Aphria (APHA), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and AdvisorShares Vice ETF (ACT). Who are Calmare Therapeutics' key executives? Calmare Therapeutics' management team includes the following people: Mr. Conrad F. Mir, Pres, CEO & Director (Age 50)Mr. Thomas Philip Richtarich M.B.A., Chief Financial Officer (Age 66)Ms. Donna J. Mays, Mang. of Admin. ServicesDr. Stephen J. D'Amato, Chief Medical Officer & Member of Medical Advisory Board (Age 71)Mr. William Lipford, Division Head of Product Sales What is Calmare Therapeutics' stock symbol? Calmare Therapeutics trades on the OTCMKTS under the ticker symbol "CTTC." How do I buy shares of Calmare Therapeutics? Shares of CTTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Calmare Therapeutics' stock price today? One share of CTTC stock can currently be purchased for approximately $0.06. How big of a company is Calmare Therapeutics? Calmare Therapeutics has a market capitalization of $1.91 million. Calmare Therapeutics employs 7 workers across the globe. What is Calmare Therapeutics' official website? The official website for Calmare Therapeutics is www.calmaretherapeutics.com. How can I contact Calmare Therapeutics? Calmare Therapeutics' mailing address is 1375 KINGS HIGHWAY EAST SUITE 400, FAIRFIELD CT, 06824. The company can be reached via phone at 203-368-6044 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
